University of Oklahoma Health Sciences Center Hematology and Medical Oncology

Topics

• Complement system in diseases 165
• Myeloproliferative Neoplasms: Diagnosis and Treatment 118
• Platelet Disorders and Treatments 107
• Cancer Immunotherapy and Biomarkers 79
• Acute Myeloid Leukemia Research 71
• Multiple Myeloma Research and Treatments 63
• Lymphoma Diagnosis and Treatment 49
• Chronic Lymphocytic Leukemia Research 45
• Hematopoietic Stem Cell Transplantation 44
• CAR-T cell therapy research 41
• Blood Coagulation and Thrombosis Mechanisms 39
• Pancreatic and Hepatic Oncology Research 36

Most cited

1. Palliative Care for Patients With Cancer: ASCO Guideline Update.

   Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024 · 279 citations · Ryan Nipp

2. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial.

   Lancet (London, England) · 2022 · 698 citations · Sami Ibrahimi

3. Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study.

   Blood · 2023 · 369 citations · Sami Ibrahimi

4. Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials.

   Nature medicine · 2023 · 334 citations · Prithviraj Bose

5. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer.

   Annals of oncology : official journal of the European Society for Medical Oncology · 2022 · 385 citations · Wajeeha Razaq

6. Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial.

   Nature medicine · 2025 · 94 citations ·